BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 03, 2006
 |  BioCentury  |  Finance

Anadys chronicles

Anadys chronicles

Anadys (ANDS) fell $3.77 (56%) to $2.92 last week after it suspended dosing in a Phase Ib trial of HCV compound ANA975. That may be drastic, as ANDS had $99.8 million in cash at March 31 and ended the first quarter with 28.4 million shares outstanding, giving the company a cash value of $3.51 per share. Even if investors ascribe no value to ANA975, the...

Read the full 308 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >